cyc 682 has been researched along with cytosine in 30 studies
*Cytosine: A pyrimidine base that is a fundamental unit of nucleic acids. [MeSH]
*Cytosine: A pyrimidine base that is a fundamental unit of nucleic acids. [MeSH]
| Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (cytosine) | Trials (cytosine) | Recent Studies (post-2010) (cytosine) |
|---|---|---|---|---|---|
| 30 | 5 | 18 | 11,168 | 142 | 3,214 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 8 (26.67) | 29.6817 |
| 2010's | 20 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YX; Endo, Y; Hayashi, Y; Matsuda, A; Morinaga, H; Obata, T; Sasaki, T; Uchida, H | 1 |
| Hanaoka, K; Hisaoka, M; Ikeda, T; Iwabuchi, H; Kaneko, M; Kobayashi, T; Kurakata, S; Matsuda, A; Mitsuhashi, Y; Miura, S; Nakagawa, A; Nomura, T; Sasaki, T; Shibayama, T; Suzuki, M; Tanaka, K; Tanzawa, F; Tomida, A; Tsuruo, T; Wataya, Y | 1 |
| Bernacki, RJ; Chaudhary, ND; Greco, W; Hoffman, RM; Kobayashi, T; Mazurchuk, R; Pera, P; Spernyak, J; Veith, J; Wu, M | 1 |
| Bouvet, M; Hoffman, RM; Katz, MH; Moossa, AR; Spivack, D; Takimoto, S | 2 |
| Braich, TA; Burch, PA; Camoriano, JK; Delaunoit, T; Erlichman, C; Kaur, JS; Kobayash, T; Reid, JM; Rubin, J | 1 |
| Galmarini, CM | 1 |
| Baker, SD; Carducci, MA; Dees, EC; Donehower, R; Gilbert, J | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Faderl, S; Gandhi, V; Kantarjian, HM | 1 |
| Boone, PA; Chiao, JH; Cortes, J; Faderl, S; Garcia-Manero, G; Green, SR; Kantarjian, H; O'Brien, S; Plunkett, W; Ravandi, F; Westwood, R | 1 |
| Choudhary, AK; Fleming, IN; Green, SR | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Baer, MR; Gojo, I | 1 |
| Burnett, AK; Hills, RK | 1 |
| Jabbour, E; Kadia, TM; Kantarjian, H | 1 |
| Kantarjian, H; Liu, X; Plunkett, W | 1 |
| Diaz, I; Muggia, F; Peters, GJ | 1 |
| Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ | 1 |
| Arellano, M; Chiao, J; Claxton, D; Coutre, S; Faderl, S; Garcia-Manero, G; Goldberg, SL; Jabbour, E; Kantarjian, H; Luger, S; Maness, L; Plunkett, W; Schiller, G; Seiter, K; Stock, W; Strickland, SA; Venugopal, P; Wetzler, M | 1 |
| Russell, NH | 1 |
| Lancet, JE | 1 |
| Furuno, T; Kurimoto, I; Obata, T; Ogawa, N; Sasaki, T; Suzuki, Y; Tanaka, M; Yamamoto, H | 1 |
| Jamieson, K; Lim, MY | 1 |
| Burnett, AK; Cahalin, P; Clark, RE; Hemmaway, C; Hills, RK; Khwaja, A; Milligan, D; Panoskaltsis, N; Russell, N | 1 |
| Norkin, M; Richards, AI | 1 |
| Blachly, JS; Ewald, B; Garzon, R; Lai, TH; Liu, C; Papaioannou, D; Plunkett, W; Sampath, D; Sulda, M; Zecevic, A | 1 |
| Al Abo, M; Huang, SY; Kiselev, E; Liu, X; Plunkett, W; Pommier, Y; Rajapakse, VN; Sasanuma, H; Takeda, S | 1 |
| Czemerska, M; Robak, T; Wierzbowska, A | 1 |
| Byrd, JC; Lai, TH; Lapalombella, R; Liu, C; Mims, A; Mitchell, S; Orwick, S; Plunkett, W; Puduvalli, VK; Ravikrishnan, J; Sampath, D; Woyach, J; Wu, PJ | 1 |
7 review(s) available for cyc 682 and cytosine
| Article | Year |
|---|---|
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cytosine; Dioxolanes; Humans; Leukemia, Myeloid, Acute; Nucleosides | 2008 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Drug Resistance; Drug Substitution; Enzyme Inhibitors; Glutathione; Glycine; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation; Sulfones; Treatment Failure | 2011 |
Sapacitabine for cancer.
Topics: Animals; Arabinonucleosides; Cell Cycle; Clinical Trials as Topic; Cytosine; DNA Damage; Drug Evaluation, Preclinical; Humans; Neoplasms; Prodrugs; Randomized Controlled Trials as Topic | 2012 |
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |
Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Cytosine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2014 |
The efficacy of sapacitabine in treating patients with acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Arabinonucleosides; Cytosine; Humans; Leukemia, Myeloid, Acute; Prognosis; Treatment Outcome | 2018 |
5 trial(s) available for cyc 682 and cytosine
| Article | Year |
|---|---|
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cytosine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms | 2006 |
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinonucleosides; Breast Neoplasms; Colorectal Neoplasms; Cytosine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prodrugs; Treatment Failure; Treatment Outcome | 2006 |
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cytosine; Drug Administration Schedule; Humans; Leukemia; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Survival Analysis | 2010 |
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Arabinonucleosides; Cytosine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Pneumonia; Thrombocytopenia | 2012 |
A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cytarabine; Cytosine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate | 2015 |
18 other study(ies) available for cyc 682 and cytosine
| Article | Year |
|---|---|
Isolation of deoxycytidine kinase from Ehrlich carcinoma cells by affinity chromatography based on a substrate analog, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-N4-palmitoylcytosine++ +.
Topics: Animals; Arabinonucleosides; Carcinoma, Ehrlich Tumor; Chromatography, Affinity; Cytosine; Deoxycytidine Kinase; Electrophoresis, Polyacrylamide Gel; Kinetics | 1999 |
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformation; Breast Neoplasms; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Deoxycytidine Kinase; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; KB Cells; Leukemia P388; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Mitomycin; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Rats, Nude; Specific Pathogen-Free Organisms; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine | 1999 |
High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.
Topics: Animals; Antineoplastic Agents; Arabinonucleosides; Cell Division; Colonic Neoplasms; Cytosine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2003 |
Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer.
Topics: Animals; Arabinonucleosides; Cell Division; Cytosine; Humans; Luminescent Proteins; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Metastasis; Pancreatic Neoplasms; Red Fluorescent Protein; Transduction, Genetic; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays | 2003 |
Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer.
Topics: Animals; Arabinonucleosides; Cell Line, Tumor; Chemotherapy, Adjuvant; Cytosine; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms | 2004 |
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cytosine; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Patents as Topic | 2006 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Death; Cell Line, Tumor; Cytosine; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Neoplasms; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Cytosine; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Nucleosides | 2012 |
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; CHO Cells; Cricetinae; Cricetulus; Cytarabine; Cytosine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Gemcitabine; Homologous Recombination; Inhibitory Concentration 50; Prodrugs | 2012 |
Improving outcomes for elderly patients with AML.
Topics: Arabinonucleosides; Cytosine; Female; Humans; Leukemia, Myeloid, Acute; Male | 2012 |
Improvement of the antitumor activity of poorly soluble sapacitabine (CS-682) by using Soluplus® as a surfactant.
Topics: Animals; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; Cytosine; Dose-Response Relationship, Drug; Mice; Polyethylene Glycols; Polysorbates; Polyvinyls; Solubility; Surface-Active Agents; Survival Analysis; Vitamin E | 2014 |
Sapacitabine in the treatment of acute myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Arabinonucleosides; Cytosine; Humans; Leukemia, Myeloid, Acute; Prognosis; Treatment Outcome | 2015 |
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Topics: Apoptosis; Arabinonucleosides; Cell Line, Tumor; Cytosine; DNA Damage; Gene Expression; HeLa Cells; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Promoter Regions, Genetic; Rad51 Recombinase; Recombinational DNA Repair | 2016 |
TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Topics: Arabinonucleosides; BRCA2 Protein; Camptothecin; Colorectal Neoplasms; Cytarabine; Cytosine; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; DNA Replication; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Phosphoric Diester Hydrolases; Poly (ADP-Ribose) Polymerase-1 | 2017 |
HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzamides; Cell Line, Tumor; Cytosine; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Leukemia, Myeloid, Acute | 2019 |